Fisher Funds Management LTD Grows Holdings in Boston Scientific Corporation $BSX

Fisher Funds Management LTD lifted its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 17.1% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,007,864 shares of the medical equipment provider’s stock after buying an additional 146,900 shares during the quarter. Boston Scientific makes up about 1.2% of Fisher Funds Management LTD’s investment portfolio, making the stock its 22nd largest holding. Fisher Funds Management LTD’s holdings in Boston Scientific were worth $43,016,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. boosted its stake in Boston Scientific by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock valued at $13,319,060,000 after acquiring an additional 1,436,550 shares during the last quarter. State Street Corp grew its holdings in Boston Scientific by 1.4% during the 4th quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock worth $6,278,422,000 after acquiring an additional 920,495 shares in the last quarter. Capital World Investors increased its position in shares of Boston Scientific by 1.9% in the 4th quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock worth $2,588,953,000 after purchasing an additional 502,627 shares during the last quarter. Norges Bank bought a new stake in shares of Boston Scientific in the 4th quarter worth about $2,199,395,000. Finally, Morgan Stanley raised its stake in shares of Boston Scientific by 10.8% in the 4th quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock valued at $2,189,289,000 after purchasing an additional 2,246,308 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling

In related news, Director Cheryl Pegus purchased 1,770 shares of the company’s stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the transaction, the director owned 1,770 shares of the company’s stock, valued at $99,987.30. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director David C. Habiger purchased 2,250 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The stock was bought at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the acquisition, the director owned 13,878 shares in the company, valued at approximately $776,057.76. The trade was a 19.35% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 204,322 shares of company stock valued at $9,939,221 over the last three months. 0.34% of the stock is owned by company insiders.

Boston Scientific Trading Up 0.4%

NYSE BSX opened at $51.40 on Thursday. Boston Scientific Corporation has a one year low of $42.20 and a one year high of $109.50. The company has a 50-day simple moving average of $45.94 and a 200-day simple moving average of $59.69. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The firm has a market capitalization of $74.49 billion, a PE ratio of 20.81, a price-to-earnings-growth ratio of 1.12 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same quarter in the prior year, the business earned $0.75 earnings per share. Boston Scientific’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities analysts forecast that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific declared that its board has approved a stock repurchase program on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s management believes its shares are undervalued.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $60.00 price target on shares of Boston Scientific in a research report on Thursday, July 30th. Stifel Nicolaus set a $60.00 price objective on Boston Scientific in a research note on Wednesday, July 29th. Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a report on Sunday, August 2nd. Wolfe Research lowered Boston Scientific from an “outperform” rating to a “peer perform” rating in a research report on Friday, May 29th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $65.00 price target on shares of Boston Scientific in a report on Friday, June 12th. Twenty-four research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $71.62.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.